211 related articles for article (PubMed ID: 35987957)
1. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
Kozma K; Dömötör ZR; Csutak A; Szabó L; Hegyi P; Erőss B; Helyes Z; Molnár Z; Dembrovszky F; Szalai E
Sci Rep; 2022 Aug; 12(1):14221. PubMed ID: 35987957
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Venkateswaran N; Mercado C; Galor A; Karp CL
Am J Ophthalmol; 2019 Mar; 199():216-222. PubMed ID: 30471241
[TBL] [Abstract][Full Text] [Related]
3. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
Sturges A; Butt AL; Lai JE; Chodosh J
Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
[TBL] [Abstract][Full Text] [Related]
4. Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.
Singh M; Gautam N; Kaur M
Int Ophthalmol; 2019 Feb; 39(2):295-301. PubMed ID: 29362973
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment for ocular surface squamous neoplasia.
Monroy D; Serrano A; Galor A; Karp CL
Eye (Lond); 2023 Apr; 37(5):885-893. PubMed ID: 36754986
[TBL] [Abstract][Full Text] [Related]
6. Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia.
Sripawadkul W; Reyes-Capo D; Zein M; Wylegala A; Albayyat G; Galor A; Karp CL
Ocul Surf; 2023 Apr; 28():108-114. PubMed ID: 36592780
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
[TBL] [Abstract][Full Text] [Related]
8. Topical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment.
Leventer I; Singh H; Pashaee B; Raimondo CD; Khakh CK; Martin JL; Acharya B; Zhang Q; Lally SE; Shields CL
Asia Pac J Ophthalmol (Phila); 2024; 13(2):100052. PubMed ID: 38521390
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review.
Viani GA; Fendi LI
Arq Bras Oftalmol; 2017; 80(2):131-136. PubMed ID: 28591290
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia.
Bahrami B; Greenwell T; Muecke JS
Clin Exp Ophthalmol; 2014; 42(4):317-22. PubMed ID: 23927413
[TBL] [Abstract][Full Text] [Related]
12. Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Wylegala A; Sripawadkul W; Zein M; Alvarez OP; Al Bayyat G; Galor A; Karp CL
Ocul Surf; 2023 Jan; 27():67-74. PubMed ID: 36476665
[TBL] [Abstract][Full Text] [Related]
13. Periocular and ocular surface nonmelanoma skin cancer.
Hooper J; Shao K; Feng PW; Falcone M; Feng H
Clin Dermatol; 2024; 42(1):71-77. PubMed ID: 37866412
[TBL] [Abstract][Full Text] [Related]
14. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
[TBL] [Abstract][Full Text] [Related]
15. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
Prabhasawat P; Tarinvorakup P; Tesavibul N; Uiprasertkul M; Kosrirukvongs P; Booranapong W; Srivannaboon S
Cornea; 2005 May; 24(4):443-8. PubMed ID: 15829803
[TBL] [Abstract][Full Text] [Related]
16. Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.
Galor A; Karp CL; Oellers P; Kao AA; Abdelaziz A; Feuer W; Dubovy SR
Ophthalmology; 2012 Oct; 119(10):1974-81. PubMed ID: 22704832
[TBL] [Abstract][Full Text] [Related]
17. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
18. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy.
Rudkin AK; Dempster L; Muecke JS
Clin Exp Ophthalmol; 2015; 43(1):20-5. PubMed ID: 24995542
[TBL] [Abstract][Full Text] [Related]
19. Interferon Alfa-2b for Pigmented Ocular Surface Squamous Neoplasia: A Report of 8 Lesions.
Kaliki S; Sharma A; Vempuluru VS
Cornea; 2021 Feb; 40(2):142-146. PubMed ID: 32355112
[TBL] [Abstract][Full Text] [Related]
20. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
Chaugule SS; Park J; Finger PT
Indian J Ophthalmol; 2018 Jan; 66(1):55-60. PubMed ID: 29283124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
